SU6668 Reduces Chondrosarcoma Growth by Targeting Blood Vessel Formation
Author Information
Author(s): Frank M Klenke, Amir Abdollahi, Elisabeth Bertl, Martha-Maria Gebhard, Volker Ewerbeck, Peter E Huber, Axel Sckell
Primary Institution: Department of Orthopedic Surgery, Inselspital, University of Bern, Switzerland
Hypothesis
The study aims to investigate the effects of SU6668 on chondrosarcoma growth, angiogenesis, and microcirculation in vivo.
Conclusion
SU6668 is a potent inhibitor of chondrosarcoma tumor growth in vivo, primarily through its antiangiogenic effects.
Supporting Evidence
- SU6668 treatment led to a 53% reduction in tumor size compared to controls.
- Functional vessel density decreased by 37% in SU6668 treated tumors.
- Histological analysis showed signs of tumor regression in SU6668 treated groups.
Takeaway
This study shows that a drug called SU6668 can help stop a type of bone cancer from growing by cutting off its blood supply.
Methodology
The study used 10 male SCID mice implanted with chondrosarcoma cells, treated with SU6668 or a control vehicle, and analyzed tumor growth and blood vessel formation through intravital microscopy.
Limitations
The study was conducted in a small animal model, which may not fully represent human responses.
Participant Demographics
10 adult male severe combined immunodeficient (SCID) mice, aged 7 to 8 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website